Short Interest in GH Research PLC (NASDAQ:GHRS) Rises By 21.1%

GH Research PLC (NASDAQ:GHRS) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 2,870,000 shares, an increase of 21.1% from the January 31st total of 2,370,000 shares. Currently, 7.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 404,900 shares, the days-to-cover ratio is currently 7.1 days.

Institutional Trading of GH Research

A number of large investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP boosted its holdings in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the period. Diadema Partners LP purchased a new position in GH Research in the fourth quarter worth $711,000. RA Capital Management L.P. raised its position in shares of GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after purchasing an additional 85,000 shares during the last quarter. Woodline Partners LP grew its holdings in shares of GH Research by 112.0% during the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after buying an additional 41,711 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in GH Research during the 4th quarter worth approximately $145,000. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Up 1.3 %

GHRS stock traded up $0.14 during trading on Thursday, reaching $10.55. The stock had a trading volume of 246,517 shares, compared to its average volume of 160,059. The stock’s 50 day moving average is $10.66 and its two-hundred day moving average is $9.19. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The firm has a market cap of $548.90 million, a PE ratio of -13.35 and a beta of 0.93.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. On average, research analysts anticipate that GH Research will post -0.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Finally, Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $30.60.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).